↓ Skip to main content

Raging the War Against Inflammation With Natural Products

Overview of attention for article published in Frontiers in Pharmacology, September 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
1 news outlet
twitter
7 X users
reddit
1 Redditor

Citations

dimensions_citation
145 Dimensions

Readers on

mendeley
241 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Raging the War Against Inflammation With Natural Products
Published in
Frontiers in Pharmacology, September 2018
DOI 10.3389/fphar.2018.00976
Pubmed ID
Authors

Ali Attiq, Juriyati Jalil, Khairana Husain, Waqas Ahmad

Abstract

Over the last few decade Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are the drugs of choice for treating numerous inflammatory diseases including rheumatoid arthritis. The NSAIDs produces anti-inflammatory activity via inhibiting cyclooxygenase enzyme, responsible for the conversation of arachidonic acid to prostaglandins. Likewise, cyclooxegenase-2 inhibitors (COX-2) selectively inhibit the COX-2 enzyme and produces significant anti-inflammatory, analgesic, and anti-pyretic activity without producing COX-1 associated gastrointestinal and renal side effects. In last two decades numerous selective COX-2 inhibitors (COXIBs) have been developed and approved for various inflammatory conditions. However, data from clinical trials have suggested that the prolong use of COX-2 inhibitors are also associated with life threatening cardiovascular side effects including ischemic heart failure and myocardial infection. In these scenario secondary metabolites from natural product offers a great hope for the development of novel anti-inflammatory compounds. Although majority of the natural product based compounds exhibit more selectively toward COX-1. However, the data suggest that slight structural modification can be helpful in developing COX-2 selective secondary metabolites with comparative efficacy and limited side effects. This review is an effort to highlight the secondary metabolites from terrestrial and marine source with significant COX-2 and COX-2 mediated PGE2 inhibitory activity, since it is anticipated that isolates with ability to inhibit COX-2 mediated PGE2 production would be useful in suppressing the inflammation and its classical sign and symptoms. Moreover, this review has highlighted the potential lead compounds including berberine, kaurenoic acid, α-cyperone, curcumin, and zedoarondiol for further development with the help of structure-activity relationship (SAR) studies and their current status.

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 241 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 241 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 32 13%
Student > Bachelor 30 12%
Researcher 22 9%
Student > Master 18 7%
Lecturer 15 6%
Other 40 17%
Unknown 84 35%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 35 15%
Pharmacology, Toxicology and Pharmaceutical Science 33 14%
Medicine and Dentistry 19 8%
Chemistry 14 6%
Agricultural and Biological Sciences 8 3%
Other 37 15%
Unknown 95 39%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 December 2023.
All research outputs
#2,733,886
of 26,208,484 outputs
Outputs from Frontiers in Pharmacology
#1,185
of 20,170 outputs
Outputs of similar age
#52,799
of 349,633 outputs
Outputs of similar age from Frontiers in Pharmacology
#32
of 397 outputs
Altmetric has tracked 26,208,484 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 20,170 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 349,633 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 397 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.